...
首页> 外文期刊>Cell death & disease. >Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin–NFAT pathway
【24h】

Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin–NFAT pathway

机译:活化的T淋巴细胞对ABT-737的耐药性:抑制钙调神经磷酸酶-NFAT途径的分子机制和可逆性

获取原文
           

摘要

Dynamic regulation of the intrinsic apoptosis pathway controls central and peripheral lymphocyte deletion, and may interfere with the pro-apoptotic potency of B-cell lymphoma 2 inhibitors such as ABT-737. By following a T-cell receptor (TCR) transgenic population of alloantigen-specific T cells, we found that sensitivity to ABT-737 radically changed during the course of allo-specific immune responses. Particularly, activated T cells were fully resistant to ABT-737 during the first days after antigen recognition. This phenomenon was caused by a TCR–calcineurin–nuclear factor of activated T cells-dependent upregulation of A1, and was therefore prevented by cyclosporine A (CsA). As a result, exposure to ABT-737 after alloantigen recognition induced selection of alloreactive T cells in vivo, whereas in combination with low-dose CsA, ABT-737 efficiently depleted alloreactive T cells in murine host-versus-graft and graft-versus-host models. Thus, ABT-737 resistance is not a prerogative of neoplastic cells, but it physiologically occurs in T cells after antigen recognition. Reversibility of this process by calcineurin inhibitors opens new pharmacological opportunities to modulate this process in the context of cancer, autoimmunity and transplantation.. ? 2012 Macmillan Publishers Limited
机译:内在凋亡途径的动态调节控制着中央和外周淋巴细胞的缺失,并可能干扰B细胞淋巴瘤2抑制剂(如ABT-737)的促凋亡能力。通过追踪同种异体抗原特异性T细胞的T细胞受体(TCR)转基因种群,我们发现对ABT-737的敏感性在同种异体免疫反应过程中发生了根本性变化。特别是,在抗原识别后的头几天,活化的T细胞对ABT-737完全耐药。这种现象是由活化T细胞依赖性A1上调的TCR-钙调神经磷酸酶-核因子引起的,因此可通过环孢霉素A(CsA)加以预防。结果,同种异体抗原识别后暴露于ABT-737诱导体内选择同种反应性T细胞,而结合低剂量CsA,ABT-737有效地耗尽了鼠类宿主与移植和移植物对T细胞的同种异体T细胞。主机模型。因此,ABT-737耐药性并不是肿瘤细胞的特权,而是在抗原识别后在T细胞中生理发生。钙调神经磷酸酶抑制剂对该过程的可逆性为癌症,自身免疫和移植过程中调节这一过程提供了新的药理学机会。 2012 Macmillan Publishers Limited

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号